Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based
therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox
preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).